We are live on ! Find out more
DNLI icon

Denali Therapeutics

18.45 USD
+0.25
1.37%
At close Updated Nov 20, 4:00 PM EST
Pre-market
After hours
18.19
-0.26
1.41%
1 day
1.37%
5 days
-1.55%
1 month
-2.54%
3 months
-26.05%
6 months
-2.02%
Year to date
13.4%
1 year
7.52%
5 years
-59.24%
10 years
-13.99%
 

About: Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.

Employees: 507

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 23.1%
Neutral 76.9%
Negative 0%
Neutral
Seeking Alpha
4 days ago
Denali Therapeutics Inc. (DNLI) Presents at UBS Global Biopharma Conference 2026 Transcript
Denali Therapeutics Inc. (DNLI) Presents at UBS Global Biopharma Conference 2026 Transcript
Denali Therapeutics Inc. (DNLI) Presents at UBS Global Biopharma Conference 2026 Transcript
Neutral
Seeking Alpha
8 days ago
Denali Therapeutics Inc. (DNLI) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
Denali Therapeutics Inc. (DNLI) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
Denali Therapeutics Inc. (DNLI) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
Positive
Seeking Alpha
8 days ago
Denali: Commercial Biotech, Scaled The Brain's Wall Once, Second Summit In Sight (Initiating Buy)
I initiate Denali Therapeutics at Buy, as the Avlayah launch has validated the TransportVehicle platform and turned DNLI into a commercial-stage story. Q3 Avlayah sales of $17.8M crushed the $10-12M guide, and Q4 guidance of $30-32M implies 65%+ sequential growth. DNL126 in Sanfilippo A is heading toward a 2027 accelerated-approval BLA and reuses the Avlayah commercial playbook almost one-for-one.
Denali: Commercial Biotech, Scaled The Brain's Wall Once, Second Summit In Sight (Initiating Buy)
Neutral
MarketBeat
8 days ago
Denali Therapeutics Targets All Eligible Hunter Disease Patients as Pipeline Milestones Near
Denali Therapeutics NASDAQ: DNLI is targeting all eligible U.S. patients for its Hunter disease treatment AVLAYAH, while preparing data updates across a pipeline that includes treatments for Sanfilippo syndrome, Pompe disease and Alzheimer's disease.
Denali Therapeutics Targets All Eligible Hunter Disease Patients as Pipeline Milestones Near
Positive
Zacks Investment Research
16 days ago
DNLI Up 7.8% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?
Denali Therapeutics gains 7.8% as Avlayah sales surge nearly fivefold, reimbursement coverage expands and multiple pipeline catalysts approach.
DNLI Up 7.8% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?
Neutral
Seeking Alpha
18 days ago
Denali Therapeutics Inc. (DNLI) Q3 2026 Earnings Call Transcript
Denali Therapeutics Inc. (DNLI) Q3 2026 Earnings Call Transcript
Denali Therapeutics Inc. (DNLI) Q3 2026 Earnings Call Transcript
Positive
MarketBeat
18 days ago
Denali Therapeutics Q3 Earnings Call Highlights
Denali Therapeutics NASDAQ: DNLI reported third-quarter 2026 net product revenue of $17.8 million from AVLAYAH, its treatment for Hunter syndrome, as expanding payer coverage and transitions of clinical-trial participants to commercial therapy supported a faster-than-expected launch.
Denali Therapeutics Q3 Earnings Call Highlights
Neutral
Zacks Investment Research
18 days ago
Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Beats Revenue Estimates
Denali Therapeutics Inc. (DNLI) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to a loss of $0.74 per share a year ago.
Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Beats Revenue Estimates
Neutral
GlobeNewsWire
18 days ago
Denali Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
AVLAYAH® (tividenofusp alfa-eknm) net product revenue accelerated to $17.8 million in its second full commercial quarter Continued growth expectations drive Q4 2026 net product revenue guidance of $30.0 million to $32.0 million AVLAYAH recognized as the “Best Biotechnology Product” of 2026 by The Galien Foundation Zafinofusp alfa advancing as Denali's second potential product, with BLA submission on track for 2027 seeking accelerated approval for Sanfilippo syndrome type A (MPS IIIA) Five TransportVehicle™ (TV) programs expected to generate data in 2027: zafinofusp alfa (ETV:SGSH), DNL593 (PTV:PGRN), DNL628 (OTV:MAPT), DNL921 (ATV:Abeta) and DNL952 (ETV:GAA) Q3 2026 net income of $70.1 million included a one-time $194.0 million net gain on the sale of a Priority Review Voucher, bringing cash, cash equivalents and marketable securities to $1.0 billion Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif.
Denali Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
Neutral
GlobeNewsWire
22 days ago
Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that AVLAYAH® (tividenofusp alfa-eknm) has been recognized as the “Best Biotechnology Product” of 2026 by The Galien Foundation. AVLAYAH is the first biologic approved by the U.S. Food and Drug Administration (FDA) that is specifically designed to cross the blood-brain barrier and reach the whole body, including the brain. AVLAYAH is an enzyme replacement therapy that received FDA accelerated approval in March 2026 for the treatment of neurologic manifestations of a rare neurodegenerative disease called Hunter syndrome (mucopolysaccharidosis type II, or MPS II) when initiated in presymptomatic or symptomatic pediatric patients weighing at least 5 kg prior to advanced neurologic impairment. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory study.
Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product
Price charts implemented using Lightweight Charts™